Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
DXCM Dexcom Inc
- Stocks
- Healthcare
- NASDAQ: DXCM
Price (delayed)
$80.245
Market cap
$31.46B
P/E Ratio
59.44
Dividend/share
N/A
EPS
$1.35
Enterprise value
$33.09B
DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring systems for diabetes management. It operates internationally with headquarters in San Diego, California. Dexcom was founded in
Highlights
Dexcom's revenue has increased by 9% YoY and by 2.9% from the previous quarter
The company's equity rose by 8% QoQ
The quick ratio has declined by 48% year-on-year but it has grown by 4.1% since the previous quarter
The stock's price to earnings (P/E) is 45% less than its 5-year quarterly average of 109.7 but 16% more than its last 4 quarters average of 52.2
The EPS fell by 18% YoY and by 8% QoQ
Dexcom's net income has decreased by 16% YoY and by 7% from the previous quarter
Key stats
What are the main financial stats of DXCM
Market
Valuations
Earnings
Shares outstanding
392.11M
Market cap
$31.46B
Enterprise value
$33.09B
Price to earnings (P/E)
59.44
Price to book (P/B)
13.83
Price to sales (P/S)
7.57
EV/EBIT
44.13
EV/EBITDA
33.93
EV/Sales
7.98
Revenue
$4.15B
Gross profit
$2.47B
Operating income
$632.6M
Net income
$535.2M
EBIT
$749.8M
EBITDA
$975M
Free cash flow
$575.2M
Per share
Balance sheet
Liquidity
EPS
$1.35
EPS diluted
$1.34
Free cash flow per share
$1.47
Book value per share
$5.8
Revenue per share
$10.61
TBVPS
$16.96
Total assets
$6.75B
Total liabilities
$4.49B
Debt
$2.53B
Equity
$2.27B
Working capital
$1.52B
Debt to equity
1.11
Current ratio
1.5
Quick ratio
1.27
Net debt/EBITDA
1.66
Margins
Efficiency
Dividend
EBITDA margin
23.5%
Gross margin
59.4%
Net margin
12.9%
Operating margin
15.3%
Return on assets
8.1%
Return on equity
24.4%
Return on invested capital
12.8%
Return on capital employed
20.2%
Return on sales
18.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
DXCM stock price
How has the Dexcom stock price performed over time
Intraday
-1.68%
1 week
12.74%
1 month
34.12%
1 year
-37.49%
YTD
3.18%
QTD
17.51%
Financial performance
How have Dexcom's revenue and profit performed over time
Revenue
$4.15B
Gross profit
$2.47B
Operating income
$632.6M
Net income
$535.2M
Gross margin
59.4%
Net margin
12.9%
The net margin has decreased by 23% YoY and by 10% from the previous quarter
Dexcom's net income has decreased by 16% YoY and by 7% from the previous quarter
The operating margin has declined by 11% year-on-year but it has increased by 2.7% since the previous quarter
Dexcom's revenue has increased by 9% YoY and by 2.9% from the previous quarter
Price vs fundamentals
How does DXCM's price correlate with its fundamentals
Growth
What is Dexcom's growth rate over time
Valuation
What is Dexcom stock price valuation
P/E
59.44
P/B
13.83
P/S
7.57
EV/EBIT
44.13
EV/EBITDA
33.93
EV/Sales
7.98
The stock's price to earnings (P/E) is 45% less than its 5-year quarterly average of 109.7 but 16% more than its last 4 quarters average of 52.2
The EPS fell by 18% YoY and by 8% QoQ
DXCM's P/B is 30% below its 5-year quarterly average of 20.1 and 3.6% below its last 4 quarters average of 14.6
The company's equity rose by 8% QoQ
The stock's price to sales (P/S) is 49% less than its 5-year quarterly average of 15.0 and 4.9% less than its last 4 quarters average of 8.1
Dexcom's revenue has increased by 9% YoY and by 2.9% from the previous quarter
Efficiency
How efficient is Dexcom business performance
The ROE is down by 17% year-on-year and by 7% since the previous quarter
Dexcom's ROA has decreased by 17% YoY and by 8% from the previous quarter
The ROS fell by 14% YoY
DXCM's return on invested capital is up by 8% since the previous quarter and by 6% year-on-year
Dividends
What is DXCM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for DXCM.
Financial health
How did Dexcom financials performed over time
The company's total assets is 51% higher than its total liabilities
The quick ratio has declined by 48% year-on-year but it has grown by 4.1% since the previous quarter
Dexcom's current ratio has decreased by 48% YoY but it has increased by 2% QoQ
The debt is 11% more than the equity
DXCM's debt to equity is down by 8% QoQ
The company's equity rose by 8% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.